• Search History (Register)
  • MeSH Browser
  • [Clear]
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canada’s Drug Agency (CDA-AMC)
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Regione Emilia Romagna
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Canada
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [3358 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Timing of enoxaparin administration for the prophylaxis of venous thromboembolism: clinical evidence and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Single-bed versus multi-bed rooms for the prevention of hospital acquired infections: clinical effectiveness and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Precautionary period for the safe handling of excreta or body fluids in patients receiving cytotoxic or antineoplastic therapy: clinical evidence and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Retesting patients with sleep apnea: guidelines and recommendations
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Hydroxyethyl starch versus other plasma volume expanders: a review of the clinical and cost-effectiveness, and guidelines for use
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Forced air warming units for adults undergoing surgery: clinical evidence
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Low molecular weight heparins versus new oral anticoagulants for long-term thrombosis prophylaxis and long-term treatment of DVT and PE: a review of the clinical and cost-effectiveness
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Long-acting beta-agonists and inhaled corticosteroids for treatment of chronic obstructive pulmonary disease: a review of the clinical efficacy and cost-effectiveness
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Non-pharmacological therapies for the treatment of insomnia in adults: clinical evidence and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Sleep medications for adults diagnosed with insomnia: clinical evidence and harms
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Summary of the exploration of the scientific literature on the effects of prostate cancer screening decision aids for the expert panel of the Collège des médecins du Québec]
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Traumatic and non-traumatic spinal cord injury: a comparative analysis of the characteristics and organization of rehabilitation care and services in Québec]
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Transcatheter aortic valve replacement in severe aortic stenosis: a review of comparative durability and clinical effectiveness beyond 12 months
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Use of prolotherapy in the treatment of chronic musculoskeletal conditions]
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Screening for sexually transmitted infections: a review of guidelines
2013     HTA Unit, University of Calgary Use of Oncotype DX for guiding adjuvant chemotherapy decisions in early stage invasive breast cancer patients in Alberta
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Notice on the reimbursement of proton pump inhibitors]
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Brentuximab for refractory CD30+ Hodgkin's lymphoma: clinical and cost-effectiveness
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Treatment and follow-up of children with sickle cell disease (SCD)]
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Administration of anesthesia by anesthesiologists versus non-physicians for patients undergoing cataract surgery: clinical effectiveness, cost-effectiveness, and guidelines
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Systemic hyperbaric oxygen therapy for the treatment of idiopathic sudden sensorineural hearing loss]
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Standing tables for adults with cerebral palsy: a review of the clinical evidence
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Overview of dabigatran usage among people insured by the public prescription drug insurance plan]
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Tools and devices for the management of dementia in older adults: review of evidence-based guidelines
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Overview of the drugs used by children and adolescents diagnosed with autism spectrum disorder who are covered by the Public Prescription Drug Insurance Plan]
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Beta human chorionic gonadotropin test for detection of early pregnancy: clinical effectiveness, cost-effectiveness, and guidelines
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Falls in patients living in health care facilities (short- and long-term care)]
2013     Institute of Health Economics (IHE) Islet transplantation for the treatment of type 1 diabetes [update]
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Use of intrathecal pumps for the treatment of chronic non-cancer pain]
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Interventions used to determine the appropriate patient populations for cataract surgery: a review of the clinical evidence and guidelines
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Self-monitoring of blood glucose in adult patients with Type 2 Diabetes not using insulin]
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Sublingual immunotherapy for respiratory allergies]
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Antimicrobial drapes for the reduction of surgical site infection: clinical effectiveness
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Efficiency of short-term social and psychological therapies: Systematic review]
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Digital screening mammography. Critical analysis of the article by Chiarelli (2013) and literature review]
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Compression bandage measurement devices for the use in adult patients with chronic venous insufficiency: clinical effectiveness
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Current strategies for optimizing the relevance of laboratory test prescription: a review of Canadian and international experiences]
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Techniques for renal biopsy: guidelines
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Patient-based funding: a literature review of experiences in other countries]
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Peripherally Inserted Central Catheters (PICCs) for adult and pediatric patients: a review of clinical evidence
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Notice regarding field trauma triage criteria]
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Vitamin D supplementation in long-term care residents: clinical evidence and guidelines
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Effectiveness of short term social and psychological interventions: a systematic review]
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) High-sensitivity cardiac troponin for the rapid diagnosis of acute coronary syndrome in the emergency department: a clinical and cost-effectiveness evaluation
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Recommendations for the use of troponin assays for rapid diagnosis of acute coronary syndrome in the emergency department
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Cataract surgery performed in settings other than hospital operating rooms: clinical effectiveness, cost-effectiveness, and guidelines
2013     Technology Assessment at SickKids (TASK) Thiopurine dosing using thiopurine methyltransferase status: a systematic review of clinical guidance
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Fecal bacteriotherapy for patients with recurrent C. difficile: clinical effectiveness and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Techniques for the management of temporary epicardial pacemaker leads: clinical evidence, safety, and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Transcatheter aortic valve replacement in severe aortic stenosis: a review of comparative durability and clinical effectiveness beyond 12 months
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Tricyclic antidepressants, clonidine, venlafaxine, and modafinil for the treatment of attention-deficit/hyperactivity disorder in adults: a review of the clinical evidence
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Probiotics in infants: clinical effectiveness, safety and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Rasburicase for adults with acute tumor lysis syndrome: a review of clinical and cost effectiveness and safety
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Patient lifts and transfer equipment for preventing pressure ulcers: a review of clinical and cost-effectiveness and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Esophageal doppler ultrasound-based cardiac output monitoring for adults undergoing surgery: a review of clinical and cost-effectiveness
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Blood glucose monitors and test strips: a review of the comparative clinical evidence and cost-effectiveness — an update
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Drug therapies for immunosuppression in adult patients following islet cell transplantation for the treatment of diabetes: clinical and cost-effectiveness
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) JC virus antibody testing for patients with MS: a review of the diagnostic accuracy and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Treatment of patients with multiple sclerosis: a review of guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Tinzaparin versus dalteparin or enoxaparin for the treatment of venous thromboembolism in adults: safety and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Techniques to improve the use of diagnostic laboratory test ordering: clinical evidence
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Antibiotic prophylaxis for patients with cardiac or orthopedic implants undergoing dental procedures: a review of the clinical effectiveness and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Biologic response modifier agents as first-line treatment for patients with rheumatoid arthritis: a review of the clinical efficacy, cost-effectiveness and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Bone morphogenetic proteins for use in spinal surgery and long bone trauma surgery: a review of the clinical effectiveness and safety
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Fecal management systems for hospitalized adult patients: comparative clinical effectiveness and safety
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Osteostimulative bone graft substitutes or demineralized bone matrix preparations for use in spinal Surgery and long bone trauma surgery: clinical effectiveness and safety
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Fusidic acid for ophthalmic infections: a review of clinical and cost effectiveness and safety
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) The timing of prophylactic antibiotics for surgery: a review of the clinical Evidence
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Computed tomography guided versus ultrasound guided renal biopsy: comparative evidence
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Prioritizing patients undergoing non-urgent, medically necessary cosmetic surgical procedures: clinical evidence and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Codeine compared with other opioids for pain relief in pediatric patients: comparative clinical effectiveness, safety, and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Meperidine to relieve shivering or bladder spasm: clinical effectiveness
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Inhaled tobramycin versus intravenous tobramycin for patients with cystic fibrosis: a review of the clinical effectiveness, cost effectiveness, and guidelines
2013     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Prevention of nephropathy by iodinated contrast media during a radiological intervention]
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Antibiotics for the prevention of post-cesarean section complications: clinical evidence and safety
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Optimal timing and frequency of follow-up care for patients receiving at-home supplemental oxygen: clinical evidence and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Wrist sphygmomanometry versus upper arm sphygmomanometry: clinical effectiveness and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) The use of dental crowns for vital and endodontically treated teeth: a review of the clinical and cost-effectiveness and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Chlorhexidine for the prevention of surgical site infections: clinical effectiveness and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Risk factors to consider for extended anticoagulant therapy: a review of guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Transcatheter aortic valve replacement
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Ondansetron for the management of chemotherapy-induced nausea and vomiting in pediatric patients: a review of the clinical effectiveness, safety and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Intranasal triamcinolone versus intranasal beclomethasone for acute and chronic sinus inflammation: a review of comparative clinical effectiveness and safety
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Thrombolytic drugs for cardiac arrest: a review of the clinical effectiveness
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Discontinuation of contact precautions for antibiotic resistant organisms: clinical evidence and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Nitrofurantoin administration in patients with renal dysfunction: clinical effectiveness, safety, and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Appropriate utilization of advanced diagnostic imaging procedures: CT, MRI, and PET/CT
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Non-urgent prenatal ultrasound: safety and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Standing orders for insulin administration in hospitalized patients with type I or type II diabetes: clinical evidence
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Shilla and MAGEC systems for growing children with scoliosis: cost-effectiveness and clinical benefits
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Probiotics for antibiotic-associated diarrhea, <i>clostridium difficile</i> infection and irritable bowel syndrome: a review of clinical evidence and safety
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) The use of medical marijuana: guidelines and recommendations
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Repetitive transcranial magnetic stimulation for specific patient populations: clinical and cost-effectiveness and safety
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Metal-ceramic versus all-ceramic dental crowns: a review of the clinical and cost-effectiveness
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Suboxone for the treatment of chronic non-cancer pain: clinical effectiveness and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Metronidazole powder and cream for odour control in acute, chronic, and palliative wounds: clinical evidence and guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Neuromuscular occlusion concept-based diagnosis and treatment of tempromandibular joint disorders: a review of the clinical evidence
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Cardiac troponin for the diagnosis of acute coronary syndrome in the emergency department: a review of guidelines
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Optimal method for driving assessment in older adults and in patients who have had a cerebrovascular accident: clinical evidence, cost-effectiveness, and guidelines